New cancer drug ALK-N001 enters early human testing
NCT ID NCT07529535
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called ALK-N001 in people with advanced solid tumors, including esophageal, lung, and stomach cancers. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Only 16 participants were enrolled, and the study is currently on hold.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- ALK-N001 (a drug given by IV infusion)
- What this could lead to
- If it works, this could point toward a new treatment option for advanced solid tumors like esophageal or lung cancer.
- What could go wrong
- This is a very early Phase 1 trial with only 16 participants, currently suspended. It primarily tests safety and dosing, so it may not lead to an effective treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCE SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhejiang Cancer Hospital
Hangzhou, 310022, China
-
Zhongshan Hospital, Fudan University
Shanghai, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Can a new infusion drug shrink Hard-to-Treat tumors?
- Tumor DNA mapping may unlock personalized cancer therapies
- Can a new drug combo shrink Hard-to-Treat tumors?
- Can donor immune cells boost lung cancer remission?
- Could adding chest radiation extend life in advanced lung cancer?